As replacement therapy for primaryhumoral immunodeficiency (PI) and secondary humoralimmunodeficiency (SI) in adult patients.

Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of patients with muscle invasive urothelial carcinoma (MIUC) who are at high risk of recurrence after undergoing radical resection of MIUC.

​For the treatment of acute graft-versus-host disease in patients aged 12 years and older who have inadequate response to corticosteroids or other​ systemic therapie​​​​s.

For routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and pediatric patients aged 12 years and older.

For the treatment of patients with metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel.

It is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease (CKD).

As addition to standard therapy for the treatment of adult patients with active, autoantibody positive, systemic lupus erythematosus (SLE).

Dayvigo (lemborexant)
is indicated for the treatment of insomnia, characterized by difficulties with
sleep onset and/or sleep maintenance.

Cariprazine is indicated as monotherapy for: Bipolar Mania: acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and Bipolar Depression: acute treatment of depressive episodes associated with bipolar I disorder in adults